New Alzheimer's drug repairs DNA damage and reduces brain inflammation

ScienceDaily reports that KCL-286, a drug originally developed for spinal cord injury, is showing promise against Alzheimer's disease. In mouse studies, it repaired harmful DNA damage and reduced brain inflammation while targeting multiple disease pathways—rather than focusing narrowly on amyloid or tau, the conventional approach. The drug has already cleared initial human safety testing, which researchers say could accelerate its path to Alzheimer's clinical trials.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton